Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development of new reverse transcriptase inhibitors].

Eiichi Kodama1

  • 1Laboratory of Virus Immunology, Research Center for AIDS, Institute for Virus Research, Kyoto University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and structure-activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein.

RSC medicinal chemistry·2026
Same author

"Is the Spanish Flu a Forgotten Pandemic?" A Survey during the COVID-19 Pandemic.

The Tohoku journal of experimental medicine·2026
Same author

Estimated Number of Mumps Cases Based on Clinical and Laboratory Data from Sentinel Surveillance in Kanazawa, Japan.

Japanese journal of infectious diseases·2025
Same author

Elucidation of Postfusion Structures of the Measles Virus F Protein for the Structure-Based Design of Fusion Inhibitors.

Journal of medicinal chemistry·2025
Same author

Janus-Type Immunofluorescent Probes and a Quantitative Immunoassay System.

Langmuir : the ACS journal of surfaces and colloids·2024
Same author

Progress Report of the Tohoku Medical Megabank Community-based Cohort Study: Study Profile of the Repeated Center-based Survey During Second Period in Miyagi Prefecture.

Journal of epidemiology·2024

Highly active antiretroviral therapy (HAART) improves HIV patient survival. This review details major anti-HIV drugs developed to combat drug-resistant HIV variants emerging during prolonged treatment.

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Context:

  • Human immunodeficiency virus (HIV) infection management has advanced significantly with highly active antiretroviral therapy (HAART).
  • HAART typically involves nucleoside (N) and non-nucleoside (NN) reverse transcriptase inhibitors (RTIs) alongside protease inhibitors.
  • Prolonged HAART can lead to the emergence of multi-drug resistant HIV variants, posing a therapeutic challenge.

Purpose:

  • To review the mechanisms of action and characteristics of major anti-HIV drugs.
  • To provide an overview of current and emerging therapeutic options for HIV treatment.
  • To address the challenge of drug resistance in HIV therapy.

Summary:

  • This review examines key anti-HIV drugs, categorizing reverse transcriptase inhibitors (RTIs) into nucleoside (N) and non-nucleoside (NN) types.

Related Experiment Videos

  • It discusses the development of novel agents to suppress replication of drug-resistant HIV variants that emerge during prolonged highly active antiretroviral therapy (HAART).
  • The mechanisms of action and properties of major drugs, both in clinical use and preclinical development, are described.

    • Impact:

    • Enhances understanding of HIV drug resistance mechanisms and therapeutic strategies.
    • Informs clinical decision-making for managing complex HIV cases.
    • Contributes to the ongoing development of more effective HIV treatments.